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The ‘worried-well’, insulin
resistance and metformin
therapy
To the Editor: I would like to respond to the letter with the
above title that appeared in a recent issue of the Journal.1 The
authors wrote: ‘The decision whether to use insulin sensitisers
in patients with impaired glucose tolerance is still being
debated, but there is certainly no evidence that these drugs will
either help the patient lose weight or prevent progression to
diabetes in individuals without dysglycaemia.’   
Metformin has been tried in obese individuals without
diabetes as a tool for inducing weight loss.  Several studies2-5
found that metformin decreased body mass index (BMI), waist-
to-hip ratio and total cholesterol and increased high-density
lipoprotein cholesterol in obese but non-diabetic patients.
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Zebras and bergkwaggas – the
case for research on rare and very
rare genetic diseases in South
Africa
To the Editor: I recently had the privilege of learning firsthand
about some very uncommon genetic diseases during a clinical
infectious diseases rotation at the National Institutes of Health
(NIH) in Bethesda, Maryland. Most of our patients had rare
inherited immunodeficiency syndromes, such as chronic
granulomatous disease and Job’s syndrome, resulting in
chronic intractable infections with unusual mycobacteria and
fungi. These patients came from around the USA, sometimes
even from other countries, for periodic elective admissions to
the hospital section for a full workup. One of our patients had
befriended a patient from another clinical section, and they
shared a ride from Virginia when they came for their annual
admissions. When I discreetly enquired what ‘zebra’ (the US
medical student term for a very rare disease) the friend might
have, the nurse replied: ‘Oh that must be the guy from Tangier
Island with Tangier disease.’ 
It turns out that Tangier disease (TD), an extremely rare (less
than 50 cases reported worldwide) genetic disorder of
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cholesterol transport, is named after an island – really a large
sand bar – located in the Chesapeake Bay, just off the coast of
Virginia.1 Settled by English watermen in the 1680s, Tangier
Island has remained a secluded enclave for more than three
centuries. The inhabitants still speak a quaint Elizabethan
dialect, and most of them bear one of four surnames from the
original group of founders. It is therefore not surprising that a
founder gene defect would eventually be expressed in such a
small gene pool. TD was first identified in a 5-year-old boy
from the island who had characteristic orange tonsils, very low
levels of high-density lipoprotein (HDL), and an enlarged liver
and spleen.2 Importantly, the low (or absent) levels of HDL in
the blood predispose TD patients to premature coronary heart
disease (CHD). The recent discovery of ABCA1 (ATP-binding
cassette A1) as the defective gene product in TD is a major
advance in lipoprotein research and has shed light on the role
of low HDL levels in CHD.3 ABCA1 is a cell membrane protein
that mediates the efflux of excess cholesterol from cells,
particularly macrophages, into the HDL metabolic pathway for
transport to the liver. Defective function of ABCA1 in TD
therefore leads to sterol-laden macrophages in tissues and
atherosclerotic plaques, as well as reduced plasma HDL.
Because of its ability to deplete macrophages of cholesterol and
to raise plasma HDL levels, ABCA1 is a promising therapeutic
target for preventing CHD, not only in TD patients but also in
the general population.3
Zebras, and even bergkwaggas, are of course not that rare in
South Africa. Several genetic disorders occur with an unusually
high frequency among South Africans. These include founder
gene disorders such as variegate porphyria (South African
genetic porphyria), familial hypercholesterolaemia, Fanconi’s
anaemia, and keratolytic winter erythema (Oudtshoorn skin
disease), which are seen particularly in the Afrikaans-speaking
population. Research on these rare, and very rare, genetic
diseases should be supported because the latter provide the
extreme conditions in humans that could show up solutions for
diseases that are much more prevalent in all South Africans.
Recent identification by the Cape Town group4 of the gene
mutation prevalent in South Africans with variegate porphyria
has already led to better diagnosis of this common and
debilitating disorder. In the era of the genomic revolution and
bioinformatics there are currently unprecedented resources
available to aid the study of genetic diseases, including an
ever-expanding number of free Internet genetic databases from
the National Center for Biotechnology Information (NCBI). In
addition, the NIH has established an Office of Rare Diseases
(ORD) to help stimulate and co-ordinate research on various
‘orphan diseases’ (less than 200 000 cases in the USA). The
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opportunity to access these powerful resources, which enable
the concentration of clinical, molecular, and computer
approaches, should be seized in order to obtain a deeper
understanding of the various genetic diseases that collectively
afflict so many South Africans.
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SAMA and sexuality – breaking
the silence
To the Editor: Jon Larsen’s letter entitled ‘Doctors and
sexuality’1 is commendable for its clear, forthright approach. It
adds an important dimension to the politically correct view
offered by the SAMJ’s Deputy Editor on the subject.2
Yes, SAMA is silent on these issues, but it should speak out
against all practices that affect the mental, physical, emotional
and spiritual health of the population. Jon Larsen’s comments
are particularly pertinent. It is indeed amazing that despite
every major religion denouncing premarital and extramarital
sex, the medical profession remains silent on the issue. To be
practical these goals may not be attainable for the majority in
our present culture, but do we give up promoting abstinence
before marriage and faithfulness within it? Do we simply cut
our losses and promote safe sex for all irrespective of any
moral considerations, even those that may impact on health?
We are inextricably linked to our consciences and if our
sexual practices do not fall in line with the fundamental
teachings of our churches, mosques and synagogues then
surely internal tension and in some cases even turmoil may
result. That this must impact on individual health is logical. We
therefore have the choice of either trying to modify our
consciences to stay in line with society’s changes, or attempting
to halt that change by speaking out against the practices we
believe will affect us and our patients at some level at some
point in time. The morality of modern day society moves
continuously in small increments in the direction it pleases, but
never without consequences. Individually and collectively the
medical profession has the choice to stand firm or follow. If we
choose the latter then what we believe to be unacceptable
today we may find acceptable tomorrow, and our practice of
medicine will become progressively more devoid of absolutes.
(It is worth recalling that in this country the legal abortion of
healthy babies on request was once regarded as morally
beyond consideration). 
In the past medical practitioners were viewed as more than
physical healers. We were held in high esteem for our
professionalism, our ethics and our adherence to high moral
standards highlighted by our Hippocratic oath.
Our silence on these aspects of sexuality may be interpreted
by many as condoning the practices outlined by Jon Larsen
while showing no regard for the health consequences of such
behaviour. It is quite likely that this will lead to our further
diminishment in the eyes of those we care for. 
Yes, SAMA should not be silent, but perhaps it is time to stop
and think about how to break that silence. If we only adhere to
what seems politically correct then the medical profession,
which has the ability to set a precedent, may lose the
opportunity to take the lead on those moral issues that impact
on the physical, mental, emotional and spiritual health of our
people.
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Legal, but is it right?
To the Editor: Specialists in private practice have the legal right
to charge whatever fees they wish, but sometimes they leave
behind frustrated people.
A 59-year-old widow developed a breast lump. The surgeon
told her that she would need ‘an operation and a
reconstruction’ and that ‘medical aid will take care of the
payment’. 
Medical aid paid the hospital fees. The surgeon’s fees were
three times higher than the medical rate. The medical aid
refused to pay the reconstructive surgeon, demanding an
adequate motivation as to why she needed reconstruction. The
widow had no extra finances. A relative paid R4 000 to the
primary surgeon over the medical aid rate and R8 000 to the
second surgeon.
When the patient tried to obtain a motivation for the
reconstructive surgery to send to the medical aid, the primary
surgeon’s practice refused to provide one. ‘This is a super-
specialist practice and not a discount supermarket. The patient
was fully informed about our fee structure,’ she was told. This
was not true! She was also told that ‘the reconstructive surgeon
must write the motivation’.
The old medico-legal adage applies. If it was not written
down, it was not done. 
